379
Views
45
CrossRef citations to date
0
Altmetric
Original Research

Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives

, , , , , , , & show all
Pages 1017-1033 | Published online: 25 Jun 2015

Abstract

With the progressive aging of the population, osteoporosis has gradually grown into a global health problem for men and women aged 50 years and older because of its consequences in terms of disabilities and fragility fractures. This is especially true in the People’s Republic of China, which has the largest population and an increasing proportion of elderly people, as osteoporosis has become a serious challenge to the Chinese government, society, and family. Apart from the fact that all osteoporotic fractures can increase the patient’s morbidity, they can also result in fractures of the hip and vertebrae, which are associated with a significantly higher mortality. The cost of osteoporotic fractures, moreover, is a heavy burden on families, society, and even the country, which is likely to increase in the future due, in part, to the improvement in average life expectancy. Therefore, understanding the epidemiology of osteoporosis is essential and is significant for developing strategies to help reduce this problem. In this review, we will summarize the epidemiology of osteoporosis in the People’s Republic of China, including the epidemiology of osteoporotic fractures, focusing on preventive methods and the management of osteoporosis, which consist of basic measures and pharmacological treatments.

Introduction

Osteoporosis (OP) can be defined as a systematic skeletal disorder characterized by low bone mass and the microarchitectural deterioration of bone tissue, with a consequent increase in the fragility of bone and susceptibility to fracture. OP can be classified into two main categories: primary OP and secondary OP. The former can occur in both males and females of all ages, but it often occurs in postmenopausal women; it also happens later in life in men. By contrast, secondary OP is the result of medication use (glucocorticoid, immunosuppressant), disease (Cushing’s syndrome, hyperparathyroidism), other conditions (vitamin D deficiency and hypogonadism), and so on.Citation1 Nowadays, OP has become a serious problem throughout the world.Citation2 In developed countries, for example, the prevalence rate of OP in older adults was about 13%–18% and 21.2% in the United States and Sweden, respectively.Citation3,Citation4 In the People’s Republic of China, however, the mean prevalence of OP in older adults is estimated at 15.7%, and it is considered to be increasing gradually with the increasing age of the total population, which is associated with the improvement of the average life expectancy. Since there were about 202.43 million people aged 60 years and older in the People’s Republic of China at the end of 2013,Citation5 the People’s Republic of China will carry a large proportion of the financial burden of OP. Moreover, because of the family planning policy in the People’s Republic of China, the ratio of older people is likely to increase significantly in the coming years.

Osteoporotic fracture related to OP is also a huge global problem. The main categories of osteoporotic fracture are: hip fracture, vertebral fracture, and distal forearm fracture. There are also other bone sites where osteoporotic fractures appear (tibia, ribs, pelvis, humerus, clavicle, fibula, etc). The cost of osteoporotic fracture, especially hip fracture, is so huge that it will have an impact on many families. Therefore, OP has received much attention in many countries of the world.Citation6,Citation7

For the management of OP, there are two types of methods. One includes basic measures such as physical exercise, changing to a healthy lifestyle, quitting smoking, supplementation of calcium and vitamin D, and so on. The other type is pharmacological treatment, and the two main categories available so far for treating OP are antiresorptives and anabolic drugs.Citation8,Citation9 However, Chinese herbal medicine is an alternative choice that is very popular in the People’s Republic of China. Therefore, this review will summarize the epidemiology and treatment of OP in the People’s Republic of China.

Definition of OP

The definition of OP can be defined in three different ways. The medical definition is that OP is a skeletal disease characterized by low bone mass, microarchitectural deterioration of bone tissue with an increase in fragility of bone, and a tendency to fracture easily. The most widely used method is the clinical definition proposed by the World Health Organization (WHO) in 1994, which is defined as bone mineral density (BMD) measurements in women that have fallen by more than 2.5 standard deviations (SDs) below the young average value.Citation10 In addition, pain, kyphosis, loss of height, and a history of fragility fracture are used as operational definitions of OP.Citation11 Therefore, in defining OP, it is important to consider both the strength of the bone and risk of fractures.

Diagnosis of OP

A clinical diagnosis should be made of individuals who sustain a low-trauma or fragility fracture. Currently in the People’s Republic of China, the most commonly used method for the diagnosis of OP is established by measuring BMD by dual-energy X-ray absorptiometry (DEXA) according to WHO diagnostic criteria.Citation12,Citation13 Based on the T-scores derived from BMD measurements of the total hip or neck of femur, the diagnosis is classified as normal, osteopenia, or OP ().Citation10,Citation14 However, for economic reasons, only the big hospitals in large cities such as Beijing, Shanghai, and some provincial capitals are equipped with DEXA equipment, which hinders the diagnosis, prevention, and treatment of OP. Research conducted in Beijing validated the OP Self-assessment Tool for Asians (OSTA) as a simple and effective tool for identifying primary OP in postmenopausal Han Chinese women. It is a calculator based on the age and body weight using the following formula:

[body weight(kg)age(year)]×0.2.15

Table 1 World Health Organization criteria for the diagnosis of osteoporosis

Epidemiology of OP in the People’s Republic of China

The People’s Republic of China has a population of more than 1.398 billion, which is 18.84% of the world’s population.Citation16 Though the annual rate of growth has dropped from 1.69% in 1996 to 1.20% at present,Citation17 the population will continue to increase gradually with the improvement of residents’ living conditions, increased average life expectancy, and the development of a social health care system. People older than 60 years accounted for 6.10% of the population in 1964 and 10.97% (about 130 million people) at the end of the 20th century; according to the Sixth National Population Census of the People’s Republic of China, it was 13.26% (about 177 million) in 2010, with those older than 65 years accounting for 8.87% of the population. Recently published data indicates that 15% (202.43 million) are older than 60 years in 2013.Citation18 Furthermore, this percentage is anticipated to reach 25% (about 400 million) by 2050.Citation19 Because of this, it has been estimated that the population with OP will increase sharply from 83.9 million in 1997 to 212 million by 2050.Citation19 All of this makes OP a major public health problem in the People’s Republic of China.

There are regional differences in the distribution of OP in the People’s Republic of China. A survey by Li et alCitation20 was conducted in five areas of the People’s Republic of China including the north (Jilin), south (Guangdong), east (Shanghai), northeast (Beijing), and southwest (Chengdu), which involved 5,593 Chinese of Han nationality selected by the stratified multistep cluster sampling method in 2002. BMD was measured and questionnaires was taken among people aged over 40 years and it was found that the prevalence rates of OP (in descending order) are as follows: Jilin (15.1%); Shanghai (14.2%); Chengdu (11.3%); Guangdong (10.2%); and Beijing (5.2%). The differences might be due to environmental, nutritional, and genetic factors. In our previous study, the relationship between body composition and fracture risk using the Fracture Risk Assessment (FRAX) model in an urban sample of central south Chinese postmenopausal women showed that 37.5% suffered from OP.Citation21

OP is mainly found in females. Epidemiologic studies have indicated that the incidence of OP in females aged 50–59 years have increased by 50%.Citation22 A large-scale study in Europe showed that OP affected only 3%–6% of men over 50 years old, but over 30% of women.Citation2 What is more, the gradient with which prevalence increases with age is steeper for females.Citation2 This phenomenon can also be seen in the People’s Republic of China. A survey conducted in Hefei in the People’s Republic of China showed that the ratio of females to males with OP is 1.61:1.0.Citation23 Most cases of OP occur in postmenopausal women, and the incidence increases with age.Citation24,Citation25 The main reasons why women are at a higher risk of OP are as follows: 1) the speed of bone loss in women after menopause is much more rapid than in men because of a significant decrease in estrogen; and 2) women have a longer life expectancy than men.Citation19 In recent years, however, the prevalence and effects of OP in men has aroused the attention of researchers and health care professionals as the population ages, and up to 25% of men aged over 50 years will experience OP. Moreover, men had less knowledge of OP than women.Citation26,Citation27 One study that investigated Chinese male’s knowledge of OP in Macau observed that the group of men aged over 55 years scored significantly lower than women, according to the Osteoporosis Knowledge Assessment Tool (OKAT).Citation28 This result is in accordance with a study conducted in Hong Kong.Citation29 Supposedly, the situation in Mainland China should be similar. Unfortunately, suffering any osteoporotic fracture leads to a higher mortality rate in men than in women.Citation30,Citation31 Therefore, it is time to highlight the care of men’s health; in connection with this, our team has established BMD reference databases for the diagnosis and evaluation of OP in the men of central southern China, which is important and useful for the detection of OP in men.Citation32 There have been few large-scale studies or surveys on male OP sufferers in Mainland China, and it is necessary and urgent to attach importance to men’s bone health as well as women’s.

Importance of osteopenia

Osteopenia occurs as the precursor of OP when BMD T-scores are between −2.5 and −1.0, according to the WHO diagnostic standard.Citation14 About 64.6% (~11.35 million) of women and 57.6% (10.04 million) of men aged 50 years or older experienced osteopenia according to statistical data from the National Health and Nutrition Examination Survey for the years 2005–2006.Citation18 Unlike the prevalence of OP in men, over 30% of men aged 50 years or older have osteopenia, which is just a little lower compared to the prevalence of OP in women. The prevalence of osteopenia, however, increases more quickly with age among elderly men compared to women.Citation33 Furthermore, it often takes several years for osteopenia to transition to OP, sometimes just 1 year for individuals with rapid severe bone loss osteopenia, and it can also lead to fragility fractures causing physical limitations, substantial morbidity, mortality, hospital care, and so on.Citation34 In the People’s Republic of China, there has been hardly any research studying the prevalence of osteopenia and its influence on populations. There was a survey about the prevalence of osteopenia in elderly patients with psychiatric disorders in Huzhou, People’s Republic of China, which showed that the prevalence of osteopenia was 33.3% and that male patients had a higher rate of osteopenia than females (42.1% versus 28.1%, respectively).Citation35 The reason for this phenomenon may be that most females developed OP (53.1% versus 5%), whereas a substantial proportion of males suffered from osteopenia. It is necessary and important to discover and even predict the risks of osteopenia, since the majority of fractures actually take place in osteopenic subjects. Because of that, the patients may be treated and preventive steps can be taken earlier to greatly decrease the rate of morbidity and mortality related to osteoporotic fractures.

Epidemiology of osteoporotic fracture

Osteoporotic fracture, one of the most severe complications of OP, is prevalent among the elderly population with OP. It is considered to be a fracture from low-energy trauma that is defined as a fall from a standing height or less, or a trauma that would not give rise to fracture in a healthy individual.Citation36 OP causes more than 8.9 million fractures annually worldwide – approximately 1,000 cases per hour.Citation37 In the People’s Republic of China, the risk of osteoporotic fractures (40%) in women is higher than the sum of the incidence of breast cancer, endometrial cancer, and ovarian cancer, while in men (at 13%), it is higher than the risk of prostate cancer.Citation38 A cross-sectional and population-based study conducted in Shanghai showed that the prevalence of osteoporotic fractures in the elderly was 15.9% in females and 14.3% in males.Citation39 A large national study in Beijing found that the prevalence of fractures was 26.6%.Citation40 In rural areas, the total prevalence rate of OP among the population over 60 years old was 8.83%,Citation18 and a rate of 14% was reported in a local study of Chongqing City.Citation41 In addition, there have been two studies related to fracture rates in Hong Kong: one reported that 30.4% of old men had at least one low-trauma fracture,Citation42 while the other reported that the rate of a history of fractures among those over 50 years old was just 6.6%.Citation43 The differences in the study samples and data collection methods may explain the huge discrepancy. The BMD measured by DEXA is the gold criterion for OP diagnosis, and it is the most available predictor of fracture in clinical practice. The risk of osteoporotic fracture increases constantly, as BMD T-scores decline from −1.5 to −3 SD;Citation44 that is to say, the lower the BMD, the higher risk of fracture will be.

BMD, however, is not the only risk factor in fracture, since fracture can also happen in the absence of OP,Citation45 maybe because of deterioration of bone quality. It is well known that bone strength is measured by both BMD and bone quality. Also, fall risk and other clinical risk factors are important in fracture prediction. Another tool for predicting the risk of fracture is the FRAX model, developed from the data of nine cohorts around the world, which uses clinical risk factors, with or without BMD, to compute the 10-year probability of hip fracture or a major osteoporotic fracture.Citation46 In Asia, there are different intervention thresholds within FRAX algorithms for some Asian countries and regions. Hong Kong researchers recommend using the Caucasian risk profile to calculate the absolute fracture risk for Hong Kong subjects.Citation47 However, when we use FRAX to estimate the 10-year risk of hip fracture in Chinese mainland women, the predicted fracture probability in Chinese mainland women was much lower than that for United Kingdom or Hong Kong Chinese women. Based on our previous study,Citation48 we have suggested that intervention in terms of both BMD testing and treatment should be recommended for individuals with a 10-year probability of major osteoporotic fracture that exceeded 4.0% or a 10-year probability of hip fracture that exceeded 1.3%. Since osteoporotic fractures characteristically occur in the areas of the skeleton with high amounts of trabeculae, the most common types of osteoporotic fractures are vertebra fractures. The other two common types of osteoporotic fractures are hip and distal forearm fractures, all of which have their own respective characteristics. Other sites for osteoporotic fractures, including the tibia, pelvis, clavicle, ribs, and so on, have also received special attention in recent years.Citation6,Citation7 The financial and health burden of osteoporotic fractures, especially hip fractures, is enormous in the People’s Republic of China because of the size of the population. One study examined the health care costs of osteoporotic fractures in a hospital in Shanghai during 2002–2004 and found that the average hospital stay was almost 1 month, and the average total cost was around RMB 12,000 (about USD 1,929).Citation49 A similar phenomenon had been found in the Chinese capital, Beijing.Citation50 In fact, these data just reflect the cost and burden of osteoporotic fracture 10 years earlier. With the aging population and changes in people’s lifestyle, both the number of OP cases and its complications (in terms of osteoporotic fracture) are coupled with a rapid increase in the total costs.Citation51 Next, we will discuss the epidemiology and characteristics of the three main categories of osteoporotic fracture.

Hip fracture

Hip fracture is most likely to be a fatal result of OP, with devastating and expensive consequences because it causes both significant morbidity and excess mortality. The total annual number of hip fractures is expected to rise from 1.3 million in 1990 to 2.6 million by 2025, and 4.5 million by 2050 worldwide.Citation52 Asia accounted for almost half of this number, most notably in the People’s Republic of China.Citation53,Citation54 Surveys conducted in Beijing,Citation55 Shenyang,Citation56 and TangshanCitation57 20 years ago showed that the rates of hip fracture were 88.0, 67.2, and 12 cases per 100,000 women and 97.0, 80.8, and 25 cases per 100,000 men, respectively. The results of all three researches are very interesting, revealing that in the age range from 50 to 55 years, the incidence of hip fracture is higher in men than in women. This probably indicates that males of that age group mainly suffer from severe force fractures related to trauma.

The incidence of hip fractures, however, increases in both males and females with increasing age, especially in females. For instance, there was a dramatic increase in the incidence of hip fractures in the population of Tangshan by 85% in men and 306% in women from that in 1994, based on the data from the Sixth National Population Census (2010).Citation57 The female to male ratio reversed to 1.03:1.0.Citation58 Analogously, the average annual number of hip fractures in people older than 50 years, according to the Beijing Ministry of Health, increased from 479 to 2,423 in women and from 441 to 1,586 in men between 1990 and 2004. In other words, the rates for those aged 50 years or older increased by 58% in women and 49% in men.Citation59 Similar trends can also be seen in other areas of the People’s Republic of China including Taiwan,Citation60 Chongqing,Citation41 and Hefei.Citation23 The growth rate of osteoporotic fractures in urban women and men was 3.34% and 3.85%, respectively, and the same rates were 3.36% and 1.00% for rural areas between 2002 and 2006. It is expected on this basis to reach 626 per 100,000 men and 1,444 per 100,000 women by 2050. That is to say, there will be 5.91 million hip fractures in 2050 in the People’s Republic of China.Citation18 In fact, the number of hip fractures is more than that in the People’s Republic of China since hip fractures in rural areas, the vast majority of patients with hip fracture choose to rest at home instead of receiving surgical treatment due to economic reasons, which leads to the underreporting of hip fractures.Citation18 These results may relate to the fact that there is a larger number of women with OP than men, and that women have a rapid loss of bone after menopause. Furthermore, the number of hip fractures and its incidence will keep on increasing with the aging population, the development of urbanization, and the changing lifestyle of people who are less likely to walk and engage in outdoor exercise and instead rely more on cars and buses.Citation38 Though severe trauma accounted for a high proportion of total hip fractures, the vast majority, however, followed a fall from standing height or less in both men and women who have low bone strength.Citation61 But in Hong Kong, the age-adjusted incidence rate of hip fracture among people aged 65 years or older decreased from 381.6 per 100,000 men and 853.3 per 100,000 women in 2001 to 341.7 and 703.1 by 2009, respectively,Citation62 a trend that has also been observed in Western countries.Citation63 This trend might be replicated in Mainland China in the future, with increased awareness and knowledge of OP, the development of the economy, and improvements of the medical insurance system.

Osteoporotic hip fractures have numerous adverse outcomes and result in high mortality among the elderly population. A person who has survived hip fracture usually exhibits decreased mobility, impaired quality of life, more dependence on family, and increased demand for medical caregivers and social services, as well as a substantial physical, mental, and financial burden.Citation64Citation66 The rate of disability is up to 50% and the mortality is as high as 15%–33% in the 1st year after hip fracture.Citation18,Citation67 What is worse is that about 28% of females and 37.5% of males die by the 2nd year.Citation68

Among all types of osteoporotic fractures in the People’s Republic of China, the cost of hip fractures is the highest. A prospective study of the economic burden of osteoporotic fractures in Western China showed that the annual total costs of hip fracture was RMB 27,283 (or USD 4,386) per person-year, followed by vertebral fracture (RMB 21,474, or USD 3,452). The annual rate of increase in cost is about 6%, and it is estimated that it will be five times of that by 2050, when the total cost for the whole country will reach RMB 1,800 billion (USD 288 billion).Citation18 Yet, the patients’ average self-declared family income was only RMB 2,307±548 (or USD 371±88) per month.Citation51 The majority of the cost is associated with direct medical care costs because the average hospital stay for hip fracture is about 22–24 days. However, the nonmedical direct costs and indirect costs also cannot be ignored. The long hospitalization makes patients prone to develop acute complications including bronchopneumonia and urinary tract infections, which occupy more medical resources.Citation69 Therefore, an osteoporotic fracture is a considerable burden, not only on the individual and family, but also on the health service system and on the whole society in the People’s Republic of China. Hence, understanding the etiology and risk factors for OP is important and significant in the prevention of hip fracture. Further research is needed to find new prevention methods and new therapies for hip fractures.

Vertebral fracture

Despite being the most common complication of OP, accounting for almost 50% of all osteoporotic fractures, vertebral fractures have received less attention compared to hip fractures.Citation70 The transition site between the more rigid and more flexible part of the spine and the mid part of the kyphotic region of the thoracic spine are the common sites of vertebral fractures.Citation71 Although vertebral fractures are often coupled with back pain, height loss, and kyphosis, a large number of vertebral fractures are asymptomatic, and the difficulty in distinguishing the causes of these physical symptoms means that only 30%–40% vertebral fractures come to medical attention.Citation72 The wedge fracture is the most common type of vertebral fracture.Citation73 Nowadays, plain radiograph, computed tomography, and magnetic resonance imaging are the most common techniques for detecting vertebral fractures.Citation74

Increasing age, increasing number of clinical risk factors, and decreasing BMD are related to the prevalence of vertebral fracture. Besides, the prevalence of vertebral fracture is increasing in association with aging. The prevalence of vertebral fractures is lower than 20% for people aged 50–69 years in Beijing, Chengdu, and Shanghai, and that of people aged 70–79 years is 19%, 25.1%, and 25.42%, respectively. For people aged over 80 years, however, the prevalence of vertebral fractures is above 36% in all three cities.Citation18 Approximately 18.1 million new vertebral fractures occur every year in the People’s Republic of China, and it is estimated that the total number of vertebral fractures will reach 367.5 million in 2020 and 485.0 million by 2050.Citation18 Research on the prevalence of vertebral fractures in Beijing indicated an incidence of about 15% among postmenopausal women, reaching 40% in women aged 80 years or older.Citation75 About 22% of subjects aged over 45 years were found to have vertebral fractures in Hong Kong, South China.Citation76 The incidence of vertebral fractures among Chinese women older than 65 years from Taiwan is 20%.Citation77 This incidence is similar to that found in Caucasian women.Citation78 For Chinese men aged over 50 years, the prevalence of vertebral fractures was about 14%. Generally, the incidence of vertebral fractures is similar to, or slightly higher, in Chinese women than in men in all age groups.Citation20

The clinical consequences of vertebral fracture include chronic disabling pain, spinal deformity with round kyphosis, pulmonary dysfunction, loss of mobility, gross impairment in activities of daily life, psychosocial disturbance (notably depression), and excess long-term mortality.Citation79 The heavy financial burden brought about by vertebral fractures is another issue. The annual cost is USD 13.8 billion in the US,Citation80 and SEK 4.6 billion (USD 0.71 billion) in Sweden.Citation81 However, there is a lack of data on the cost of vertebral fractures in the People’s Republic of China, but it is likely that the amounts involved would draw attention. Besides this, vertebral fracture is a risk factor for both future vertebral and nonvertebral fractures, such as hip fractures.Citation82,Citation83 Therefore, understanding the prevalence of vertebral deformities and the risk factors for vertebral fractures would help doctors to make appropriate decisions and focus their attention on the diagnosis and prevention of OP, since the majority of vertebral fractures are independent of falls and are clinically silent.

Distal forearm fracture

Distal forearm fracture has a different age distribution from vertebral or hip fractures. The incidence increases linearly from ages 40 to 65 years.Citation84 This may be related to the patterns of falling with advancing age. In general, about one-half of cases are due to tripping or slipping; these may be the most frequent causes of falls among elderly patients. Another one-fifth are due to syncope, one-fifth to one-third are due to a loss of balance, and the remainder are the result of miscellaneous factors.Citation85 In men, however, the incidence rates stay relatively constant between the ages of 20 years and 80 years. The female to male ratio is about 4:1. The most common type of distal forearm fractures is the Colles’ fracture, mainly caused by falling outdoors. The peak incidence of distal forearm fractures often occurs in winter, particularly during periods of icy weather.Citation86 Though less than 20% of distal forearm fracture patients are hospitalized, it does not appear to cause significant mortality compared with hip fractures;Citation37 the influence of this should not be neglected. In women with a distal forearm fracture, the functions related to the upper extremity (meal preparation, heavy housekeeping, shopping) and social roles will be limited in the early period after injury, and their psychological health will also be impaired.Citation87 In addition, the average cost of the 1st year after distal forearm fracture was approximately RMB 8,828 (or USD 1,419) per person in the People’s Republic of China between 2010 and 2012,Citation51 and about 40% of the cost was for hospitalization. This characteristic is similar to that found in some developed countries.Citation81,Citation88,Citation89 Nevertheless, very few studies have been published so far on the incidence of distal forearm fracture in the People’s Republic of China, and it needs much more technical and financial resources to conduct a comprehensive and complete epidemiological survey due to the large population involved.

Risk factors for OP

Understanding the risk factors for OP is significant for several reasons: 1) it can help us to understand the pathophysiology of the disorder; 2) it can help in the treatment of individual patients; 3) it is available to support preventive strategies against OP and fractures; and 4) it can be helpful in decreasing the incidence of OP and fractures.

The risk factors for OP can be classified into different categories: general factors; body composition; lifestyle; dietary factors; genetic factors; and secondary factors ().

Table 2 Risk factors for osteoporosis

General factors

Females are more likely to have OP, since estrogen loss takes place rapidly after menopause. As age is the absolute risk factor for OP, with advancing age, the incidence of OP obviously increases. Some studies have indicated that weight is a protective factor for OP, since it can protect against fracture by cushioning and absorbing the impact of a fall, and given that it reduces the likelihood of hip fracture due to falls.Citation90,Citation91,Citation92 Our study, and another previous study, also showed that postmenopausal nonobese women with type 2 diabetes have a lower BMD and higher OP rate,Citation93,Citation94 but now, more surveys are confirming that high body mass index (BMI) is also a risk factor for OP, especially for the overweight population. Another risk factor is height: tall people have a greater risk of OP than shorter individuals.Citation95

Body composition

Traditionally, body composition comprises fat mass and lean mass. Lean mass has been found to be positively associated with BMD at all bone sites, and it is a protective factor for OP.Citation96 But the relationship between fat mass and OP is, however, controversial.Citation97,Citation98 There are different opinions about the different BMI levels and the distinct value criteria.Citation99

Dietary factors

Vitamin D deficiency status has been defined as having serum 25-hydroxyvitamin D (25[OH]D) levels <50 nmol/L (20 ng/mL).Citation100 The People’s Republic of China covers a large area, and regions at different latitudes receive different amounts of sunlight, but in almost every city, the phenomenon of insufficient vitamin D status is found, including in Beijing,Citation101 Shanghai,Citation102 Shenyang,Citation103 Lanzhou,Citation104 and even Hong Kong.Citation105 Our recent nationwide cross-sectional multicenter study of serum 25(OH)D levels among postmenopausal women in the People’s Republic of China demonstrated that vitamin D deficiency and insufficiency are common among postmenopausal women in the People’s Republic of China, especially during the winter and among those living in urban areas. Our study recruited 1,688 women with a mean age of 65.4 years, and our results showed that 61.4% of these postmenopausal women had a serum 25(OH) D level <20 ng/mL. The overall prevalence was 91.2% for 25(OH)D <30 ng/mL and 37.6% for 25(OH)D <15 ng/mL.Citation106 Many studies have shown that low vitamin D levels are associated with increased OP and fracture incidence.Citation107Citation109

The main reasons for vitamin D deficiency are twofold: a lack of adequate exposure to sunlight; and shortage of a dietary vitamin D source. A Chinese diet based on plant proteins, apart from being low in calcium content, also lacks high vitamin D content.Citation110

Lifestyle

It is well known that physical activity is beneficial to the skeleton, and that the restriction of physical activity and immobility lead to bone loss.Citation111 However, with the economic development and improvement of people’s living standards, a sedentary lifestyle that depends much more on cars and buses is popular among the Chinese, which is harmful to BMD. Moreover, mahjong is a very popular entertainment activity in the People’s Republic of China, which results in long periods of sitting, even causing mahjong-related deep vein thrombosis.Citation112 In addition, cigarette smoking, alcohol drinking, and high levels of caffeine intake can decrease BMD in women and men, thus increasing the risk of OP.Citation113,Citation114

Genetic factors

OP is a polygenetic disorder disease, and gene–gene interactions may play a key role in determining the risk of the disease. What is more, BMD is a highly heritable trait, with heritability estimated at 50%–80%.Citation115 Several susceptibility genes for OP, including OPG, RANK, RANKL, ZBTB40, ESR1, LRP4, LRP5, MARK3, MHC, SPTBN1, and SOST, have been revealed.Citation116,Citation117 Moreover, six OP susceptibility genes (ESR1, LRP5, OPG, RANK, ZBTB40, and SOST) have been found to be associated with BMDs in a Han Chinese population,Citation118 and Li et alCitation119 found that GALNT3 plays a role in the genetic susceptibility to OP among Chinese postmenopausal women. Besides, a family history of fracture is also associated with an increased risk of OP and fracture in an older population, particularly in older women.Citation120

Secondary factors

Factors causing secondary OP can be grouped into two categories: medications and diseases. Glucocorticoids are one of the most common medications to induce OP.Citation121 Other medications consist of immunosuppressants, heparin, anticonvulsants, thiazolidinediones, proton pump inhibitors, and so on.Citation122 Numerous diseases are known to cause bone loss and OP, including endocrine disorders (malnutrition, hyperthyroidism, hyperparathyroidism, Cushing’s syndrome, hypogonadism), gastrointestinal diseases (primary biliary cirrhosis, Crohn’s disease, hemochromatosis, inflammatory bowel disease, pancreatic diseases), hematologic diseases (multiple myeloma, systemic mastocytosis, leukemia, thalassemia, lymphoma), and other disorders (such as rheumatoid arthritis, stroke, depression).Citation75,Citation114

Management of OP

OP is a condition that is often asymptomatic or even “silent” until a fracture occurs. Fracture, consequently, is always associated with significant morbidity, mortality, and a heavy economic burden. Therefore, attaching more importance to preventing and detecting younger patients and selecting appropriate treatment for those who are already affected is important in the prevention of OP-related fractures. Two kinds of methods are used in the People’s Republic of China to decrease the risk of OP and its related effects: basic measurements and pharmacologic treatments.Citation38,Citation123

Basic measurements

Basic measurements are indispensable for the prevention of OP and for decreasing the incidence of osteoporotic fractures. Basic measurements are not only suitable for the primary and secondary prevention of OP, but they can also be used during periods of drug treatment or rehabilitation therapy for OP for the entire population. The main basic measurements for preventing OP are as follows.

Lifestyle adjustment

Lifestyle and patients’ behavior are associated with OP and fractures. Tai Ji Quan or square dancing are popular among the Chinese people. Patients should generally avoid cigarette smoking, and the excessive consumption of alcohol and caffeine.Citation113,Citation114 Moreover, tea is very popular with Chinese people, and previous studies have demonstrated that tea consumption is a protective factor in maintaining BMD.Citation124 However, the relationship between tea intake and the risk of OP and fracture is inconsistent.Citation125Citation127 A sedentary lifestyle or inactivity, which accelerate bone loss, should be avoided among elderly people as much as possible.

Nutrition counseling

To maintain bone health, adults should maintain a balanced diet that is rich in calcium, has adequate vitamin D, low salt, and appropriate amounts of protein. The Chinese Society of Nutrition recommends that 800 mg per day of calcium for adults is beneficial for obtaining peak bone mass in young people, and at least 1,000 mg per day for postmenopausal women and the older population.Citation38 Moreover, vitamin D is essential for the absorption of calcium, and there is increasing recognition of its critical role in bone health, so the supplementing of calcium must be coupled with vitamin D. Adequate exposure to sunlight is beneficial for the synthesis of vitamin D through the skin. A daily intake of 600–800 IU should be recommended for the older population and 800–1,200 IU for OP patients,Citation38 which is in accordance with the National Osteoporosis Foundation’s recommendations.Citation128 The International Osteoporosis Foundation suggests that the level of 25(OH)D should not be below 30 ng/mL (75 nmol/L) in order to decrease the risk of falls and fractures.

Central obesity is a negative factor for bone metabolism. An inverse relationship has been found between the ratio of visceral adipose tissue/subcutaneous adipose tissue and BMD, which might be the result of obesity-induced chronic inflammation. However, weight reduction might not have a negative effect on bone metabolism when there is adequate calcium intake.Citation129,Citation130

Physical exercise

Exercise plays an important role in the management of osteoporotic patients and can result in a myriad of positive benefits, such as the achievement of peak bone mass, a reduction in the risk of OP, and the building or maintenance of bone strength.Citation131 Weight-bearing, muscle-strengthening, and balance-training exercises are particularly helpful for improving agility, strength, posture, coordination, and balance, thus reducing the risk of a fall. Recommended activities include walking, jogging, aerobics, stair climbing, field or racquet sports, dancing, and Tai Ji Quan, a traditional Chinese martial art.Citation79 However, the severity and progression of the patient’s bone loss, as well as the location of any previous fractures, should be taken into account. Hence, OP patients should avoid flexion-biased exercises such as abdominal crunches, lifting heavy weights, and excessive twisting or bending.Citation132

Reducing fall risk

Falling plays a critical role in most osteoporotic fractures, and fall prevention is important for patients with OP.Citation133 Fall prevention strategies involve checking and correcting vision problems related to age as quickly as possible, evaluating neuromuscular coordination and cognitive function, improving proprioceptive and vestibular systems, reviewing adverse effects of medications (dizziness, hypoglycemia, orthostatic hypotension) and promoting exercise.Citation134,Citation135 Another factor that should be given more attention is environmental modification consisting of minimizing safety hazards in the home (installing grab bars/handrails near toilets, providing adequate lighting, providing appropriate shoes, altering slippery and wet surfaces, and eliminating obstructions).Citation136 In addition, some assistive devices, such as properly-fitted canes and walkers, and certain types of joint protectors are also useful to facilitate a steadier gait and reduce the risk of a fall.Citation137

Reasonable application of glucocorticoid and bone loss prevention

By using the equivalent of prednisone 5 mg/day for 3–6 months, BMD has been shown to decrease rapidly, and the risk of fracture has increased dramatically (relative ratio [RR] value: any fracture, 1.33~1.91; hip fracture, 1.61~2.01; vertebral fracture, 2.60~2.86; and forearm fracture, 1.09~1.13). Fractures induced by glucocorticoids have three characteristics:Citation138,Citation139 first, the risk of fracture has nothing to do with age, sex, and basic diseases; second, hip or rib fracture can still occur even with the normal BMD, therefore, there seems to be no safe dose of glucocorticoid to avoid bone loss and fractures; and third, muscle weakness and myopathy can reduce the ability to balance, which leads to falling and fracturing easily.

The guidelines for the diagnosis and treatment of glucocorticoid-induced OP (GIOP) in the People’s Republic of China point out that patients who require the long-term use of glucocorticoids should be measured for BMD every 6–12 months.Citation140 Glucocorticoid treatment is defined as less than 3 months for the short term, 3~6 months for the short-to-medium term, and more than 6 months for the long term.Citation141 The American College of Rheumatology recommended that patients treated with glucocorticoids (the equivalent dose to prednisone >5 mg/day) for more than 3 months should take the following treatment measures:Citation142 first, they should make improvements to their lifestyle (no smoking and drinking less); second, they should engage in appropriate weight-bearing exercise; third, they should take supplements of calcium and vitamin D; and fourth, they should take bisphosphonates (however, premenopausal women should be careful). If patients require the long-term use of glucocorticoids, and there is an already existing risk for developing OP, preventive measures should be taken more imminently. Apart from improving lifestyle, engaging in appropriate weight-bearing exercise, and supplementing calcium and vitamin D, hormone replacement therapy (HRT) should be adopted in a timely way (when there is gonadal dysfunction or other clinical indications), and lumbar spine or hip BMD should be measured regularly.Citation138 When the BMD T-score is <−1, bisphosphonates should be given, and if the patients are contraindicated for or intolerant to bisphosphonates, we recommended teriparatide or denosumab as an alternative choice, but considering the price and convenience of the two drugs in the People’s Republic of China, calcitonin becomes the second choice for most patients. If the BMD is normal, patients should be followed up every 1~2 years, coupled with a measurement of BMD.Citation143

At present, agreement has not yet been reached in every country with respect to the prevention and treatment of GIOP, but all the guidelines point out that steps should be taken to measure BMD where there is long-term use of glucocorticoids.Citation144Citation146 Most opinions suggest that bisphosphonates should be taken as the first-line treatment with supplements of calcium and vitamin D, which are the basic drugs for primary and secondary prevention. In 2010, the American College of Rheumatology updated its guidelines for the prevention and treatment of GIOP, focusing on the following points:Citation142 first, when planning to use a glucocorticoid, measurements should be taken to prevent and treat GIOP, especially the timely supplementation of calcium and vitamin D; second, bisphosphonates, such as zoledronic acid, are the first choice of treatment; and third, common vitamin D is useful for decreasing the bone loss induced by low and medium doses of glucocorticoid, but it has no protective effect on OP induced by a high dose of glucocorticoid.

There are five aspects to the prevention of GIOP, which are set out as follows:Citation138,Citation143,Citation147 first, avoid the abuse of glucocorticoids as much as possible, and nonglucocorticoid medication should be taken as the first choice by patients. Second, choose the best dosage, usage, and course of treatment. Patients who are used to glucocorticoids should take topical remedies as much as possible in order to reduce the dosage and side effects of glucocorticoids. In addition, oral treatment should be taken as an alternative day therapy, so as to keep the feedback function of the hypothalamic–pituitary–adrenal axis. Third, treatment with the agents should be reduced, or even terminated, as soon as the disease is controlled, and if patients need the long-term use of glucocorticoids, the lowest effective dose is recommended. In the past, a daily dose of 7.5 mg of prednisone (5 mg in the morning, 2.5 mg in the afternoon) was regarded as the “physiological” requirement, but many of these patients have also suffered from GIOP.Citation148 Multifactorial analysis has shown that 24-hour urinary cortisol/creatinine excretion is a good index to judge whether the cortisol is excessive or not, and it is a predictor of BMD. Fourth, a combination using antiosteoporotic drugs (for example, using bisphosphonates first, and then activated vitamin D or sex hormones) should be used to prevent GIOP. Last, BMD should be measured regularly.

Suggestions for solving the problems faced by the People’s Republic of China concerning OP

In order to solve the problems that exist in the People’s Republic of China about OP, we proposed a number of suggestions, as follows: first, continue to increase the basis for and clinical study investment of preventing OP and improve the quality of research pertaining to the epidemiology of OP by governmental and nongovernmental methods. Second, strengthen the professional teaching of OP, have doctors engage in OP education as on-the-job continuing education training content (so as to improve the understanding of OP), and encourage medical staff to pay more attention to OP. Third, improve the ability to diagnose and treat OP by setting up specialized OP outpatient services, and offer different equipment (DEXA or ultrasonic instruments) according to different levels of hospitals and economic situations; if this is done, patients with back pain or osteoporotic fractures can be diagnosed and treated earlier. Fourth, enhance popular science education and improve the awareness of OP among people, especially those at high risk for OP. Most importantly, establish a healthy lifestyle of drinking more milk, engaging in more exercise, and increasing sun exposure, which is the key to increasing adolescent peak bone mass and maintaining young bone health.Citation18 Therefore, everyone should understand that no one is immune to OP, and that it is a silent disease that is present before a fragility fracture occurs, which people can do much to prevent.

Pharmacologic treatment

The guidelines for the prevention and treatment of OP proposed by the Chinese Society of Osteoporosis and Bone Mineral Research (CSOBMR) in the People’s Republic of ChinaCitation38 recommends pharmacological treatment for the following indications: 1) postmenopausal women and men aged 50 years or older (they should be considered for treatment if they have a hip or vertebral fracture, including a fragility fracture); 2) a Dual Energy X-ray Absorptiometry (DEXA) T-score below −2.5 at the femoral neck or spine after excluding other secondary causes; 3) an osteopenic patient with a T-score of −1.0 to −2.5, and with at least one risk factor for OP with or without fracture; and 4) an Osteoporosis Self-assessment Tool for Asians (OSAT) screening for high risk and a 10-year probability of a major osteoporotic fracture of at least 20%, or a hip fracture risk of at least 3% (based on FRAX).

The drugs approved by the State Food and Drug Administration for the treatment and prevention of OP can be classified into two categories: antiresorptive agents and anabolic agents. Antiresorptive agents include bisphosphonates, calcitonin, HRT, selective estrogen receptor modulators, and denosumab. Anabolic agents consist of teriparatide and intact parathyroid hormone (PTH), while another mixed bone-forming and antiresorptive drug is strontium ranelate. Their specific effects on the prevention and treatment of OP are shown in . Besides, Chinese herbal medicine is a popular alternative treatment in the People’s Republic of China. The goal of all treatment is to build bone and reduce the risk of fracture.

Table 3 Medications for the prevention/treatment of OP

Traditional Chinese medicine

In the People’s Republic of China, people are looking for complementary or alternative medicines to treat OP. Traditional Chinese medicines have been used to treat bone-related diseases for thousands of years in the People’s Republic of China.Citation149,Citation150 A study of their mechanisms has shown that some Chinese herbal medicines have an estrogen-like effect, which was considered to be due to phytoestrogens,Citation151 and they may induce osteoblast differentiation and osteogenesis.Citation152 It has been demonstrated that some Chinese herbal medicines have therapeutic anti-OP effects in animal modelsCitation153,Citation154 or in postmenopausal women.Citation155 However, due to the lack of large multicenter samples and rigorous control studies to identify the anti-OP effect of Chinese herbal medicines, they have only been recommended as alternative or supplementary medications for OP treatment at the present stage. It is well known that there are plenty of natural resources with an osteogenesis effect, either in the form of medicinal herbs or bioactive components. Further work should therefore be done to investigate their mechanisms and adverse effects by means of clinical investigations in a strict multicenter, randomized control study before their clinical use.

Combination therapies

The combined application of antiosteoporotic drugs is more complex, bearing in mind the interaction between drugs. By combining bisphosphonates and HRT, BMD increased more in the lumbar spine and hip when compared with either agent alone.Citation177 But several noted studies showed that the concurrent use of bisphosphonates and PTH attenuated the anabolic effects of PTH on BMD, rather than obtaining addictive effects in vivo and in vitro.Citation178Citation180 However, starting the drugs sequentially rather than simultaneously – that is to say, treatment with PTH several months before adding bisphosphonates – was associated with a greater and more rapid increase in BMD at the lumbar spine and hip.Citation181 Nevertheless, the combination of denosumab and teriparatide improved BMD at the spine and hip more than with either denosumab or teriparatide alone in patients with severe OP.Citation182,Citation183 Further research is still needed to determine whether these combinations result in improved fracture protection, and their long-term safety implications should be considered.

Future prospects

With an increase in life expectancy and the aging of the population in the People’s Republic of China, the number of people with OP will increase greatly in future generations. This is coupled with a mounting number of osteoporotic fractures, which will have a far-reaching and devastating impact on the individuals themselves, and also on the health service, economy, and population as a whole because of the high rates of morbidity and mortality, and the heavy economic burden. Fortunately, many of the risk factors for this disease are well recognized, and models for predicting the probability of OP are currently being developed, making OP preventable. Moreover, measurements should be taken to prevent OP and enable therapy for OP to be provided. Other than the common drugs mentioned earlier, there are also some other osteoporotic drugs, such as novel selective estrogen receptor modulators (bazedoxifene),Citation184 antisclerostin antibodies (sclerostin),Citation185 cathepsin K inhibitors (odanacatib),Citation186 and stem cell therapy,Citation187 which act more directly on bone-forming pathways to enhance bone formation without provoking an osteoclast-mediated bone-resorptive response. It will take several years for these to be applied in clinical practice, however, before Phase III trials are finished. In fact, weighing the data on side effects, the cost of the drugs, the effects compared with the already available drugs, the risk rate of osteoporotic fractures, and the patients’ perspectives are critical when making decisions about the treatment of OP. Of course, nonpharmacological interventions (adequate calcium and vitamin D supply, regular exercise, the prevention of falls, smoking cessation, limited alcohol intake, etc) are also important. Therefore, a good understanding of the epidemiology of OP and osteoporotic fractures can help identify those at greatest risk and permit the appropriate targeting of treatment for the prevention of fractures. As with other chronic diseases, each patient should make a lifelong plan for OP prevention and treatment.

Acknowledgments

This work was supported by funding from the National Natural Science Foundation of China (grant number 81270962), the National Basic Research Program of China (973 Program) (2014CB942903), the Program for New Century Excellent Talents in University (NCET-13-0601), and the Fundamental Research Funds for the Central Universities of Central South University (Grant NO. 2015zzts313).

Disclosure

The authors report no conflicts of interest in this work.

References

  • Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosisAm J Med19939466466508506892
  • O’NeillTWFelsenbergDVarlowJCooperCKanisJASilmanAJThe prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis StudyJ Bone Miner Res1996117101010188797123
  • LookerACOrwollESJohnstonCCJrPrevalence of low femoral bone density in older U.S. adults from NHANES IIIJ Bone Miner Res19971211176117689383679
  • KanisJAJohnellOOdenAJonssonBDe LaetCDawsonARisk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosisBone200027558559011062343
  • Ministry of Civil Affairs released 2013 Social Services Development Statistics Bulletin [webpage on the Internet]Ministry of Civil Affairs of the People’s Republic of China Available from http://www.mca.gov.cn/article/zwgk/mzyw/201406/20140600654488.shtmlAccessed May 21, 2015
  • GuilleminFMartinezLCalvertMFear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international studyOsteoporos Int201324123001301023754200
  • HarveyNCMatthewsPCollinsRCooperCUK Biobank Musculoskeletal Advisory GroupOsteoporosis epidemiology in UK Biobank: a unique opportunity for international researchersOsteoporos Int201324122903290524057481
  • FontenotHBHarrisALPharmacologic management of osteoporosisJ Obstet Gynecol Neonatal Nurs2014432236245
  • LevineJPPharmacologic and nonpharmacologic management of osteoporosisClin Cornerstone200681405317591575
  • Assessment of fracture risk and its application to screening for postmenopausal osteoporosis Report of a WHO Study GroupWorld Health Organ Tech Rep Ser199484311297941614
  • KungAWFanTXuLFactors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective studyBMC Womens Health201313723410131
  • KanisJADelmasPBurckhardtPCooperCTorgersonDGuidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone DiseaseOsteoporos Int1997743904069373575
  • KanisJAGlüerCCAn update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis FoundationOsteoporos Int200011319220210824234
  • KanisJAMeltonLJ3rdChristiansenCJohnstonCCKhaltaevNThe diagnosis of osteoporosisJ Bone Miner Res199498113711417976495
  • YangYWangBFeiQValidation of an osteoporosis self-assessment tool to identify primary osteoporosis and new osteoporotic vertebral fractures in postmenopausal Chinese women in BeijingBMC Musculoskelet Disord20131427124053509
  • Geohive [homepage on the Internet]Global Population Statistics Available from www.geohive.comAccessed 21 May, 2015
  • National Bureau of Statistics of the People’s Republic of China [homepage on the Internet]China Statistical Yearbook Available from http://www.stats.gov.cn/tjsj/ndsj/Accessed 21 May, 2015
  • XuanQingyunInterpretation for the “White paper of Osteoporosis prevention in China” in the twelfth orthopaedic academic conference of Chinese Medical Association and the fifth COA International Academic Conference2010ChengduSichuan province of ChinaChinese
  • LiuZHZhaoYLDingGZZhouYEpidemiology of primary osteoporosis in ChinaOsteoporos Int19977Suppl 3S84S879536309
  • LiNOuPZhuHYangDZhengPPrevalence rate of osteoporosis in the mid – aged and elderly in selected parts of ChinaChin Med J (Engl)2002115577377512133555
  • ZhangZShenXZhangHThe relationship between body composition and fracture risk using the FRAX model in central south Chinese postmenopausal womenClin Endocrinol (Oxf)201277452453022469329
  • LöfmanOBerglundKLarssonLTossGChanges in hip fracture epidemiology: redistribution between ages, genders and fracture typesOsteoporos Int2002131182511878451
  • WangJWangYLiuWDWangFYinZSHip fractures in Hefei, China: the Hefei osteoporosis projectJ Bone Miner Metab201432220621423784553
  • DhanwalDKCooperCDennisonEMGeographic variation in osteoporotic hip fracture incidence: the growing importance of Asian influences in coming decadesJ Osteoporos2010201075710220981334
  • El MaghraouiANgbandaARBensaoudNBensaoudMRezqiATaziMAAge-adjusted incidence rates of hip fractures between 2006 and 2009 in Rabat, MoroccoOsteoporos Int20132441267127322736070
  • DohenyMOSedlakCAEstokPJZellerROsteoporosis knowledge, health beliefs, and DXA T-scores in men and women 50 years of age and olderOrthop Nurs200726424325017882102
  • JubyAGDavisPA prospective evaluation of the awareness, knowledge, risk factors and current treatment of osteoporosis in a cohort of elderly subjectsOsteoporos Int200112861762211580074
  • WongCPLokMKWunYTPangSMChinese men’s knowledge and risk factors of osteoporosis: compared with women’sAm J Mens Health20148215916624027205
  • LeeLYLaiEKOsteoporosis in older Chinese men: knowledge and health beliefsJ Clin Nurs200615335335516466485
  • CenterJRNguyenTVSchneiderDSambrookPNEismanJAMortality after all major types of osteoporotic fracture in men and women: an observational studyLancet1999353915687888210093980
  • BliucDNguyenNDMilchVENguyenTVEismanJACenterJRMortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and womenJAMA2009301551352119190316
  • WuXPHouYLZhangHEstablishment of BMD reference databases for the diagnosis and evaluation of osteoporosis in central southern Chinese menJ Bone Miner Metab200826658659418979158
  • DonaldsonMGCawthonPMLuiLYOsteoporotic Fractures in Men (MrOS) Study GroupEstimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelinesJ Bone Miner Res20102571506151120200971
  • GourlayMLFineJPPreisserJSStudy of Osteoporotic Fractures Research GroupBone-density testing interval and transition to osteoporosis in older womenN Engl J Med2012366322523322256806
  • GuoPWangSZhuYPrevalence of osteopenia and osteoporosis and factors associated with decreased bone mineral density in elderly inpatients with psychiatric disorders in Huzhou, ChinaShanghai Arch Psychiatry201224526227025328349
  • MeltonLJ3rdThamerMRayNFFractures attributable to osteoporosis: report from the National Osteoporosis FoundationJ Bone Miner Res199712116239240721
  • JohnellOKanisJAAn estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporos Int200617121726173316983459
  • China Medical Association of Osteoporosis and Bone Mineral ResearchGuidelines for diagnosis and treatment of primary osteoporsis (2011)Chinese Journal of Osteoporosis and Bone Mineral Research201141217 Chinese
  • LiuJMMaLYBiYFA population-based study examining cal-caneus quantitative ultrasound and its optimal cut-points to discriminate osteoporotic fractures among 9352 Chinese women and menJ Clin Endocrinol Metab201297380080922170722
  • HuoDLiLA case – control study on risk factors for hip fracture in the middle – aged and elderly in BeijingZhonghua Liu Xing Bing Xue Za Zhi20002113740 Chinese11860756
  • JiangBQZhongPHChengXBYangXLYangJCaoYFInvestigation of health and nutrition status of middle-aged and old residents in the urban district of ChongqingAsia Pac J Clin Nutr200716Suppl 1172117392070
  • CheungEYHoAYLamKFTamSKungAWDeterminants of bone mineral density in Chinese menOsteoporos Int200516121481148616133639
  • LauEMLeungPCKwokTThe determinants of bone mineral density in Chinese men – results from Mr Os (Hong Kong), the first cohort study on osteoporosis in Asian menOsteoporos Int200617229730316175311
  • MarshallDJohnellOWedelHMeta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracturesBMJ19963127041125412598634613
  • StoneKLSeeleyDGLuiLYOsteoporotic Fractures Research GroupBMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic FracturesJ Bone Miner Res200318111947195414606506
  • KanisJAJohnellOOdenAJohanssonHMcCloskeyEFRAX and the assessment of fracture probability in men and women from the UKOsteoporos Int200819438539718292978
  • TsangSWKungAWKanisJAJohanssonHOdenATen-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scoresOsteoporos Int200920111939194519326036
  • ZhangZOuYShengZLiaoEHow to decide intervention thresholds based on FRAX in central south Chinese postmenopausal womenEndocrine201445219519724146412
  • PeifangWThe cost statistic of osteoporotic fracture treatment from 2000 to 2004Chinese Journal of Osteoporosis200603274277 Chinese
  • LuoLZXuLStudy on direct economic-burden and its risk factors of osteoporotic hip fractureZhonghua Liu Xing Bing Xue Za Zhi2005269669672 Chinese16471214
  • QuBMaYYanMThe economic burden of fracture patients with osteoporosis in western ChinaOsteoporos Int20142571853186024691649
  • GullbergBJohnellOKanisJAWorld-wide projections for hip fractureOsteoporos Int1997754074139425497
  • CooperCColeZAHolroydCRIOF CSA Working Group on Fracture EpidemiologySecular trends in the incidence of hip and other osteoporotic fracturesOsteoporos Int20112251277128821461721
  • CummingsSRXuLChenXZhaoXYuWGeQBone mass, rates of osteoporotic fractures, and prevention of fractures: are there differences between China and Western countries?Chin Med Sci J1994931972007865845
  • XuLLuAZhaoXChenXCummingsSRVery low rates of hip fracture in Beijing, People’s Republic of China the Beijing Osteoporosis ProjectAm J Epidemiol199614499019078890668
  • YanLZhouBPrenticeAWangXGoldenMHEpidemiological study of hip fracture in Shenyang, People’s Republic of ChinaBone19992421511559951786
  • ZhangLChengABaiZEpidemiology of cervical and trochant-eric fractures of the proximal femur in 1994 in Tangshan, ChinaJ Bone Miner Metab2000182848810701163
  • TianFMZhangLZhaoHYLiangCYZhangNSongHPAn increase in the incidence of hip fractures in Tangshan, ChinaOsteoporos Int20142541321132524562838
  • XiaWBHeSLXuLRapidly increasing rates of hip fracture in Beijing, ChinaJ Bone Miner Res201227112512921956596
  • WangCBLinCFLiangWMExcess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort studyBone201356114715323727435
  • HahnBHOsteoporosis: diagnosis and managementBull Rheum Dis1988382193071392
  • ChauPHWongMLeeALingMWooJTrends in hip fracture incidence and mortality in Chinese population from Hong Kong 2001–2009Age Ageing201342222923323204430
  • BrauerCACoca-PerraillonMCutlerDMRosenABIncidence and mortality of hip fractures in the United StatesJAMA2009302141573157919826027
  • HaentjensPAutierPBaretteMVenkenKVanderschuerenDBoonenSHip Fracture Study GroupSurvival and functional outcome according to hip fracture type: a one-year prospective cohort study in elderly women with an intertrochanteric or femoral neck fractureBone200741695896417913614
  • ShyuYIChenMCLiangJLuJFWuCCSuJYChanges in quality of life among elderly patients with hip fracture in TaiwanOsteoporos Int20041529510214605800
  • StrömOBorgstromFZethraeusNLong-term cost and effect on quality of life of osteoporosis-related fractures in SwedenActa Orthop200879226928018484255
  • EkmanEFThe role of the orthopaedic surgeon in minimizing mortality and morbidity associated with fragility fracturesJ Am Acad Orthop Surg201018527828520435878
  • JiangHXMajumdarSRDickDADevelopment and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fracturesJ Bone Miner Res200520349450015746995
  • BaudoinCFardellonePBeanKOstertag-EzembeAHervyFClinical outcomes and mortality after hip fracture: a 2-year follow-up studyBone1996183 Suppl149S157S8777081
  • CummingsSRMeltonLJEpidemiology and outcomes of osteoporotic fracturesLancet200235993191761176712049882
  • SuzukiNOgikuboOHanssonTThe course of the acute vertebral body fragility fracture: its effect on pain, disability and quality of life during 12 monthsEur Spine J200817101380139018751742
  • KungAWEpidemiology and diagnostic approaches to vertebral fractures in AsiaJ Bone Miner Metab200422317017515108057
  • SuzukiNOgikuboOHanssonTThe prognosis for pain, disability, activities of daily living and quality of life after an acute osteo-porotic vertebral body fracture: its relation to fracture level, type of fracture and grade of fracture deformationEur Spine J2009181778819082846
  • GraziottiPJGraziottiCRSangsterAMSignificance of preoperative MRI in establishing levels of augmentation for percutaneous vertebro-plastyJ Pain Res2013635936523690700
  • LingXCummingsSRMingweiQVertebral fractures in Bei-jing, China: the Beijing Osteoporosis ProjectJ Bone Miner Res200015102019202511028456
  • KwokAWGongJSWangYXPrevalence and risk factors of radiographic vertebral fractures in elderly Chinese men and women: results of Mr OS (Hong Kong) and Ms OS (Hong Kong) studiesOsteoporos Int201324387788522707064
  • TsaiKTwuSChiengPYangRLeeTPrevalence of vertebral fractures in Chinese men and women in urban Taiwanese communitiesCalcif Tissue Int19965942492538781047
  • TsangSWBowCHChuEYYeungSCSoongCCKungAWClinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with vertebral fractureOsteoporos Int201122266767420503038
  • IpICheungSKCheungTCOSHK Task Group for Formulation of 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong KongOsteoporosis Society of Hong KongThe Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong KongHong Kong Med J201319Suppl 214023535738
  • TruumeesEOsteoporosisSpine (Phila Pa 1976)200126893093211317115
  • BorgströmFZethraeusNJohnellOCosts and quality of life associated with osteoporosis-related fractures in SwedenOsteoporos Int200617563765016283064
  • LindsayRSilvermanSLCooperCRisk of new vertebral fracture in the year following a fractureJAMA2001285332032311176842
  • HasseriusRKarlssonMKNilssonBERedlund-JohnellIJohnellOEuropean Vertebral Osteoporosis StudyPrevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis StudyOsteoporos Int2003141616812577186
  • CooperCMeltonLJ3rdEpidemiology of osteoporosisTrends Endocrinol Metab19923622422918407104
  • DiasJJAn analysis of the nature of injury in fractures of the neck of the femurAge Ageing19871663733773425483
  • JacobsenSJSargentDJAtkinsonEJO’FallonWMMeltonLJContribution of weather to the seasonality of distal forearm fractures: a population-based study in Rochester, MinnesotaOsteoporos Int19999325425910450415
  • EdwardsBJSongJDunlopDDFinkHACauleyJAFunctional decline after incident wrist fractures – Study of Osteoporotic Fractures: prospective cohort studyBMJ2010341c332420616099
  • PikeCBirnbaumHGSchillerMSharmaHBurgeREdgellETDirect and indirect costs of non-vertebral fracture patients with osteoporosis in the USPharmacoeconomics201028539540920402541
  • HäusslerBGotheHGölDGlaeskeGPientkaLFelsenbergDEpidemiology, treatment and costs of osteoporosis in Germany – the BoneEVA StudyOsteoporos Int2007181778417048064
  • ReidIRRelationships between fat and boneOsteoporos Int200819559560617965817
  • LiuSLiJShengZWuXLiaoERelationship between body composition and age, menopause and its effects on bone mineral density at segmental regions in Central Southern Chinese postmenopausal elderly women with and without osteoporosisArch Gerontol Geriatr2011532192197
  • HsuYHVennersSATerwedowHAFengYNiuTRelation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and womenAm J Clin Nutr200683114615416400063
  • ShanPFWuXPZhangHCaoXZYuanLQLiaoEYAge-related bone mineral density, osteoporosis rate and risk of vertebral fracture in mainland Chinese women with type 2 diabetes mellitusJ Endocrinol Invest201134319019620808073
  • ZhouYLiYZhangDWangJYangHPrevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetesDiabetes Res Clin Pract201090326126920950884
  • HannanMTFelsonDTDawson-HughesBRisk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis StudyJ Bone Miner Res200015471072010780863
  • ShengZXuKOuYRelationship of body composition with prevalence of osteoporosis in central south Chinese postmenopausal womenClin Endocrinol (Oxf)201174331932421114512
  • BlumMHarrisSSMustALeptin, body composition and bone mineral density in premenopausal womenCalcif Tissue Int2003731273214506951
  • MoritaYIwamotoIMizumaNPrecedence of the shift of body-fat distribution over the change in body composition after menopauseJ Obstet Gynaecol Res200632551351616984520
  • KangDHGuoLFGuoTAssociation of body composition with bone mineral density in northern Chinese men by different criteria for obesityJ Endocrinol Invest Epub2014925
  • NormanAWBouillonRWhitingSJViethRLipsP13th Workshop consensus for vitamin D nutritional guidelinesJ Steroid Biochem Mol Biol20071033–520420517234402
  • FooLHZhangQZhuKRelationship between vitamin D status, body composition and physical exercise of adolescent girls in BeijingOsteoporos Int200920341742518629568
  • LuLYuZPanAPlasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individualsDiabetes Care20093271278128319366976
  • YanLPrenticeAZhangHWangXStirlingDMGoldenMMVitamin D status and parathyroid hormone concentrations in Chinese women and men from north-east of the People’s Republic of ChinaEur J Clin Nutr2000541687210694775
  • ZhenDLiuLGuanCZhaoNTangXHigh prevalence of vitamin D deficiency among middle-aged and elderly individuals in northwestern China: its relationship to osteoporosis and lifestyle factorsBone2015711625284157
  • WatWZLeungJYTamSKungAWPrevalence and impact of vitamin D insufficiency in southern Chinese adultsAnn Nutr Metab2007511596417356256
  • XiaZZXiaZWuWHigh prevalence of vitamin D insuffi-ciency and deficiency among postmenopausal women in ChinaThe 7th International Conference on Osteoporosis and Bone Metabolism Abstract2014
  • RoyDKBerryJLPyeSRVitamin D status and bone mass in UK South Asian womenBone200740120020416950669
  • KuchukNOPluijmSMvan SchoorNMLoomanCWSmitJHLipsPRelationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older personsJ Clin Endocrinol Metab20099441244125019158198
  • LiSOuYZhangHVitamin D status and its relationship with body composition, bone mineral density and fracture risk in urban central south Chinese postmenopausal womenAnn Nutr Metab2014641131924642634
  • WooJLeungSSHoSCLamTHJanusEDDietary intake and practices in the Hong Kong Chinese populationJ Epidemiol Community Health1998521063163710023462
  • NelsonMEFiataroneMAMorgantiCMTriceIGreenbergRAEvansWJEffects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trialJAMA199427224190919147990242
  • ZhangGSPengHLDengMYMah-Jong-related deep vein thrombosisLancet20103759733221420609966
  • NelsonHDNevittMCScottJCStoneKLCummingsSRSmoking, alcohol, and neuromuscular and physical function of older women. Study of Osteoporotic Fractures Research GroupJAMA199427223182518317990216
  • CenterJRBliucDNguyenTVEismanJARisk of subsequent fracture after low-trauma fracture in men and womenJAMA2007297438739417244835
  • IoannidisJPNgMYShamPCMeta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone massJ Bone Miner Res200722217318317228994
  • RichardsJBRivadeneiraFInouyeMBone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association studyLancet200837196231505151218455228
  • StyrkarsdottirUHalldorssonBVGretarsdottirSNew sequence variants associated with bone mineral densityNat Genet2009411151719079262
  • LiuJMZhangMJZhaoLAnalysis of recently identified osteoporosis susceptibility genes in Han Chinese womenJ Clin Endocrinol Metab2010959E112E12020554715
  • LiNWangXJiangYAssociation of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture studyMenopause201421551552124045674
  • CummingsSRNevittMCBrownerWSRisk factors for hip fracture in white women. Study of Osteoporotic Fractures Research GroupN Engl J Med1994332127677737862179
  • NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and TherapyOsteoporosis prevention, diagnosis, and therapyJAMA2001285678579511176917
  • KhoslaSBilezikianJPThe role of estrogens in men and androgens in womenEndocrinol Metab Clin North Am200332119521812699299
  • LevineJPPharmacologic and nonpharmacologic management of osteoporosisClin Cornerstone200681405317591575
  • WuCHYangYCYaoWJLuFHWuJSChangCJEpidemiological evidence of increased bone mineral density in habitual tea drinkersArch Intern Med200216291001100611996609
  • KeramatAPatwardhanBLarijaniBThe assessment of osteoporosis risk factors in Iranian women compared with Indian womenBMC Musculoskelet Disord200892818304358
  • Hernández-AvilaMStampferMJRavnikarVACaffeine and other predictors of bone density among pre- and perimenopausal womenEpidemiology1993421281348452901
  • Hamdi KaraIAydinSGemalmazAHabitual tea drinking and bone mineral density in postmenopausal Turkish women: investigation of prevalence of postmenopausal osteoporosis in Turkey (IPPOT Study)Int J Vitam Nutr Res200777638939718622949
  • BerrySDKielDPDonaldsonMGApplication of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis StudyOsteoporos Int2010211536019937426
  • TranHAPetrovskyNPregnancy-associated osteoporosis with hypercalcaemiaIntern Med J2002329–1048148512380703
  • PerisPGuañabensNMonegalAPregnancy associated osteoporosis: the familial effectClin Exp Rheumatol200220569770012412203
  • ErnstEExercise for female osteoporosis. A systematic review of randomised clinical trialsSports Med19982563593689680658
  • BonnerFJSinakiMGraboisMHealth professional’s guide to rehabilitation of the patient with osteoporosisOsteoporos Int200314Suppl 2S1S2212759719
  • GrissoJAKelseyJLStromBLRisk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study GroupN Engl J Med199132419132613312017229
  • Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics SocietySummary of the Updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older personsJ Am Geriatr Soc201159114815721226685
  • Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause SocietyMenopause20101712554 quiz 55–5620061894
  • WolfSLBarnhartHXKutnerNGMcNeelyECooglerCXuTReducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention TechniquesJ Am Geriatr Soc19964454894978617895
  • LimMRHuangRCWuAGirardiFPCammisaFPJrEvaluation of the elderly patient with an abnormal gaitJ Am Acad Orthop Surg200715210711717277257
  • BachmeyerCGauthierMHow to prevent glucocorticoid-induced osteoporosisCleve Clin J Med20107711762 author reply 76221086710
  • PereiraRMCarvalhoJFCanalisEGlucocorticoid-induced osteoporosis in rheumatic diseasesClinics (Sao Paulo)201065111197120521243296
  • The Chinese Society of Osteoporosis and Bone Mineral ResearchTreatment guideline of glucocorticoid-induced osteoporosischin j gen pract200608460461 Chinese
  • Chinese Medical Association of RheumatologyExperts consensus on diagnosis and treatment of glucocorticoid-induced osteoporosisChinese Journal of Rheumatology2013176363368 Chinese
  • GrossmanJMGordonRRanganathVKAmerican College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Care Res (Hoboken)201062111515152620662044
  • RouxCRajzbaumGMorelGManagement of glucocorticoid-induced osteoporosis: lessons for clinical practiceJoint Bone Spine201178Suppl 2S222S22622153676
  • VenuturupalliSRSacksWReview of new guidelines for the management of glucocorticoid induced osteoporosisCurr Osteoporos Rep201311435736424114241
  • Glucocorticoid induced osteoporosis treatment guidelinesChinese Journal of General Practitioners200608460461
  • SuzukiYNawataHSoenSFujiwaraSNakayamaHGuidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 updateJ Bone Miner Metab201432433735024818875
  • ChopinFHoppéEMorelGBiverEBorgSThomasTSelecting the optimal treatment for glucocorticoid-induced osteoporosisJoint Bone Spine201178Suppl 2S218S22122153675
  • BriotKCortetBRouxCFardetLAbitbolV2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosisJoint Bone Spine201481649350125455041
  • ZhaoYHWangMWProgress of experimental research on prevention and treatment of osteoporosis by traditional Chinese medicineZhongguo Zhong Xi Yi Jie He Za Zhi2003231294394514714372
  • DuGCaoCReview on experiment of traditional Chinese medicine treating to osteoporosisZhongguo Zhong Yao Za Zhi201136440140421598528
  • LagariVSLevisSPhytoestrogens in the prevention of postmenopausal bone lossJ Clin Densitom201316444544924090647
  • GuoAJChoiRCCheungAWBaicalin, a flavone, induces the differentiation of cultured osteoblasts: an action via the Wnt/beta-catenin signaling pathwayJ Biol Chem201128632278822789321652696
  • LiCRZhangGWNiuYBPanYLZhaiYKMeiQBAntiosteopo-rosis effect of radix scutellariae extract on density and microstructure of long bones in tail-suspended sprague-dawley ratsEvid Based Complement Alternat Med2013201375370324223617
  • LiuMXiaoGGRongPSemen Astragali Complanati- and Rhizoma Cibotii-enhanced bone formation in osteoporosis ratsBMC Complement Altern Med20131314123782721
  • ZhuHMQinLGarneroPThe first multicenter and random-ized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosisOsteoporos Int20122341317132721505910
  • WattsNBDiabDLLong-term use of bisphosphonates in osteoporosisJ Clin Endocrinol Metab20109541555156520173017
  • SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)200012111210746426
  • BoneHGHoskingDDevogelaerJPAlendronate Phase III Osteoporosis Treatment Study GroupTen years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med2004350121189119915028823
  • HarringtonJTSte-MarieLGBrandiMLRisedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosisCalcif Tissue Int200474212913514648009
  • WhitakerMGuoJKehoeTBensonGBisphosphonates for osteoporosis – where do we go from here?N Engl J Med2012366222048205122571168
  • DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone2008421364217920005
  • BlackDMDelmasPDEastellRHORIZON Pivotal Fracture TrialOnce-yearly zolendronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
  • ChesnutIII CHSkagAChristiansenCOral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
  • ChesnutCH3rdSilvermanSAndrianoKA randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study GroupAm J Med2000109426727610996576
  • CauleyJARobbinsJChenZWomen’s Health Initiative InvestigatorsEffects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trialJAMA2003290131729173814519707
  • SimonJAWehrenLEAscott-EvansBHOmizoMKSilfenSLLom-bardiASkeletal consequences of hormone therapy discontinuance: a systematic reviewObstet Gynecol Surv200661211512416433935
  • DelmasPDEnsrudKEAdachiJDMulitple Outcomes of Ral-oxifene Evaluation InvestigatorsEfficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialJ Clin Endocrinol Metab20028783609361712161484
  • EttingerBBlackDMMitlakBHReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA1999282763764510517716
  • NelsonHDSmithMEGriffinJCFuRUse of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task ForceAnn Intern Med2013158860461423588749
  • CummingsSRSan MartinJMcClungMRFREEDOM TrialDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
  • DelmasPDClinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseasesJ Clin Densitom200811232533818375161
  • WattsNBLewieckiEMMillerPDBaimSNational Osteoporosis Foundation 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologistJ Clin Densitom200811447347718562228
  • NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
  • BaronRHesseEUpdate on bone anabolics in osteoporosis treatment: rationale, current status, and perspectivesJ Clin Endocrinol Metab201297231132522238383
  • MeunierPJRouxCSeemanEThe effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med2004350545946814749454
  • ReginsterJYSeemanEDe VernejoulMCStrontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) studyJ Clin Endocrinol Metab20059052816282215728210
  • PinkertonJVDalkinACCombination therapy for treatment of osteoporosis: a reviewAm J Obstet Gynecol2007197655956518060937
  • WuXPangLLeiWInhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodelingCell Stem Cell20107557158021040899
  • FinkelsteinJSWylandJJLeeHNeerRMEffects of teriparatide, alendronate, or both in women with postmenopausal osteoporosisJ Clin Endocrinol Metab20109541838184520164296
  • BlackDMGreenspanSLEnsrudKEPaTH Study InvestigatorsThe effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med2003349131207121514500804
  • MuschitzCKocijanRFahrleitner-PammerALungSReschHAntiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral densityJ Bone Miner Res201328119620522836585
  • BucklandJOsteoporosis: Teriparatide and denosumab: two drugs are better than one!Nat Rev Rheumatol20139738323712125
  • TsaiJNUihleinAVLeeHTeriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trialLancet20133829886505623683600
  • MillerPDChinesAAChristiansenCEffects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled studyJ Bone Miner Res200823452553518072873
  • ClarkeBLAnti-sclerostin antibodies: utility in treatment of osteoporosisMaturitas201478319920424842796
  • BaronRKneisselMWNT signaling in bone homeostasis and disease: from human mutations to treatmentsNat Med201319217919223389618
  • GuanMYaoWLiuRDirecting mesenchymal stem cells to bone to augment bone formation and increase bone massNat Med201218345646222306732